Immediate Impact
2 from Science/Nature 65 standout
Citing Papers
Bispecific and multispecific antibodies in oncology: opportunities and challenges
2024 Standout
The anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial
2024 Standout
Works of Beate Rautenberg being referenced
Randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC).
2018
A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors
2018
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Beate Rautenberg | 224 | 37 | 37 | 84 | 64 | 19 | 330 | |
| Bogang Wu | 168 | 33 | 42 | 95 | 49 | 20 | 350 | |
| Eriseld Krasniqi | 184 | 89 | 93 | 55 | 36 | 21 | 314 | |
| Aude-Marie Savoye | 153 | 31 | 45 | 69 | 17 | 19 | 298 | |
| Anja Schmid | 115 | 17 | 24 | 45 | 72 | 14 | 310 | |
| Cristina Cotarelo | 122 | 42 | 65 | 35 | 36 | 20 | 306 | |
| Dorette S. van Ingen Schenau | 102 | 56 | 17 | 84 | 20 | 16 | 346 | |
| George Mo | 158 | 48 | 26 | 79 | 12 | 17 | 318 | |
| Susanne Wingert | 136 | 24 | 47 | 141 | 51 | 17 | 369 | |
| László Márkász | 180 | 61 | 29 | 120 | 16 | 22 | 371 | |
| Xiang Xu | 101 | 43 | 60 | 45 | 19 | 32 | 296 |
All Works
Loading papers...